2026-04-13T03:59:19Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2128892025-12-05T16:00:26Zcom_2072_1057col_2072_478860col_2072_478917

00925njm 22002777a 4500 dc Nuñez, Alexa author Pons, Mònica author Esquinas López, Cristina author Torres-Durán, María author Rodríguez-Hermosa, Juan Luis author Calle, Myriam author Tubio-Pérez, Ramón author Belmonte, Irene author Rodríguez-Frías, Francisco author Rodríguez, Esther author Genescà, Joan author Miravitlles Fernández, Marc author Barrecheguren, Miriam author 2024-06-12T14:40:18Z 2024-06-12T14:40:18Z 2021-04-16 2024-06-12T14:40:23Z Screening of liver disease in alpha-1 antitrypsin deficiency (AATD) is usually carried out with liver enzymes, with low sensitivity. We conducted a multicenter cross-sectional study aiming to describe the utility of transient elastography for the identification of liver disease in patients with AATD. A total of 148 AATD patients were included. Among these, 54.7% were Pi*ZZ and 45.3% were heterozygous for the Z allele. Between 4.9% and 16.5% of patients had abnormal liver enzymes, without differences among genotypes. Liver stiffness measurement (LSM) was significantly higher in Pi*ZZ individuals than in heterozygous Z (5.6 vs. 4.6 kPa; p = 0.001). In total, in 8 (5%) individuals LSM was >7.5 kPa, considered significant liver fibrosis, and ≥10 kPa in 3 (1.9%) all being Pi*ZZ. Elevated liver enzymes were more frequently observed in patients with LSM > 7.5 kPa, but in 5 out of 8 of these patients all liver enzymes were within normal range. In patients with AATD, the presence of abnormal liver enzymes is frequent; however, most of these patients do not present significant liver fibrosis. Transient elastography can help to identify patients with liver fibrosis even with normal liver enzymes and should be performed in all Z-allele carriers to screen for liver disease. Alfa 1-antitripsina Ultrasons en medicina Malalties del fetge Alpha 1-antitrypsin Ultrasonics in medicine Liver diseases Utility of transient elastography for screening of liver disease in patients with alpha1-antitrypsin deficiency.